Vanderbilt University School of MedicineDisclosures
Dr. Roden receives royalties on a patent related to predicting drug-induced arrhythmias. He is currently a consultant to Merck, Novartis, Astellas, Sanofi, Dai-ichi Sankyo.
Dr. Dan Roden is professor of medicine and pharmacology and assistant vice-chancellor for personalized medicine at Vanderbilt University School of Medicine.
Dr. Roden received his medical degree and training in internal medicine from McGill Universityin Montreal and then trained at Vanderbilt in clinical pharmacology and cardiology. His career-long focus has been studies of the clinical, genetic, cellular, and molecular basis of arrhythmia susceptibility and variability responses to arrhythmia therapies.
He acted as North American coordinator for the Fondation Leducq "Alliance Against Sudden Cardiac Death" Trans-Atlantic Network of Excellence (2005-2010). Over the last 10 years, he has led Vanderbilt's broader efforts in pharmacogenomics discovery and implementation. Dr. Roden is Principal Investigator for the Vanderbilt sites of the NIH's Pharmacogenomics Research Network (where he currently serves as chair of the steering committee) and the NHGRI's Electronic Medical Records and Genomics Network. He directs BioVU, the Vanderbilt DNA databank that currently links DNA samples from >100,000 patients to deidentified electronic medical records.
Dr. Roden served as director of the Vanderbilt Arrhythmia Service, director of the division of clinical pharmacology (1992-2004), and in 2006 was named assistant vice-chancellor for Personalized Medicine. Dr. Roden has received the Leon Goldberg Young Investigator Award and the Rawls Palmer Progress in Science Award from the American Society for Clinical Pharmacology and Therapeutics and the Distinguished Scientist Award from the Heart Rhythm Society. He has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians.
You need to be logged in to save this episode to a playlist.